Compare · OGN vs TXMD

OGN vs TXMD

Side-by-side comparison of Organon & Co. (OGN) and TherapeuticsMD Inc. (TXMD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both OGN and TXMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • OGN is the larger of the two at $3.65B, about 170.3x TXMD ($21.4M).
  • OGN has hit the wire 10 times in the past 4 weeks while TXMD has been quiet.
  • OGN has more recent analyst coverage (19 ratings vs 2 for TXMD).
MetricOGNTXMD
Company
Organon & Co.
TherapeuticsMD Inc.
Price
-
-
Market cap
$3.65B
$21.4M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
10
0
Recent ratings
19
2
OGN

Organon & Co.

Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.

TXMD

TherapeuticsMD Inc.

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Latest OGN

Latest TXMD